Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been given a consensus rating of “Moderate Buy” by the twenty-seven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, fourteen have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $93.9545.

Several research firms recently commented on EW. Mizuho increased their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Citigroup reaffirmed a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, October 8th.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,465 shares of company stock valued at $3,804,610 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences in the second quarter worth $889,000. Randolph Co Inc purchased a new position in Edwards Lifesciences in the second quarter valued at about $301,000. OMERS ADMINISTRATION Corp increased its position in Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $1,760,000. Finally, Arkadios Wealth Advisors purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $300,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 1.1%

Shares of EW stock opened at $85.26 on Thursday. The stock has a 50-day simple moving average of $84.45 and a 200 day simple moving average of $79.83. The stock has a market capitalization of $49.48 billion, a P/E ratio of 36.75, a P/E/G ratio of 3.87 and a beta of 0.97. Edwards Lifesciences has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the company earned $0.67 EPS. Edwards Lifesciences’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts expect that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.